Atossa Therapeutics, Inc.
ATOS
$0.6231
$0.01812.99%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 15.25% | 9.79% | 18.04% | -4.34% | -11.62% |
| Total Depreciation and Amortization | -26.09% | 145.45% | 160.00% | 177.78% | 187.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -47.33% | -56.58% | -76.35% | -1.54% | 12.07% |
| Change in Net Operating Assets | -70.51% | 177.83% | 519.01% | 551.97% | 353.59% |
| Cash from Operations | -0.43% | 1.72% | 12.78% | 18.72% | -0.87% |
| Capital Expenditure | -35.71% | 13.64% | 62.96% | -42.86% | 48.15% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -35.71% | 99.06% | 99.79% | 99.58% | 99.70% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | 100.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 349.02% | 120.61% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 22.53% | 17.45% | 24.03% | 27.92% | 11.99% |